Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 130Carboplatin 127Cisplatin 118Paclitaxel 99Gemcitabine 87Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 62Cyclophosphamide 61Pemetrexed 59Capecitabine 56Bevacizumab 56durvalumab 52Oxaliplatin 52Fluorouracil 50Doxorubicin 49Radiotherapy 48Leucovorin 45Radiation 44Rituximab 43Lenalidomide 42Vincristine 39Etoposide 36Nivolumab 34atezolizumab 33Letrozole 32130-nm albumin-bound paclitaxel 32Irinotecan 31Prednisone 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × dalpiciclib × 90 days × Clear all
NCT07467330 2026-03-12

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

Fujian Cancer Hospital

Phase 3 Recruiting
258 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡